Analyzing Analyst Ratings for Editas Medicine (EDIT) Stock
April 4, 2023
Trending News 🌥️
Analysts’ ratings for Editas Medicine ($NASDAQ:EDIT) Inc. (EDIT) stock have been growing steadily in the past several months, and investors are eager to understand the reasoning behind this trend. As a leading company in the rapidly growing field of gene editing and precision medicine, Editas Medicine is an attractive choice for many investors. This article will explore the various ratings given by analysts for EDIT stock, offering a deeper analysis of the trends and factors that are impacting the ratings. Editas Medicine is a biotechnology company that specializes in gene editing and precision medicine. Through the development of advanced therapeutic modalities, Editas Medicine is aiming to revolutionize medicine and create treatments for a wide variety of conditions. Analysts from various institutions have been closely tracking Editas Medicine’s progress, resulting in various ratings for their stock.
While some analysts have given EDIT a ‘buy’ rating and advise investors to purchase their stock, others have been more conservative and suggested that investors should wait for a better valuation before purchasing. Furthermore, analysts have noted that the company’s strong financial performance, strong clinical data, and numerous collaborations give EDIT a great potential for further growth. Overall, it is clear that analysts’ ratings for Editas Medicine Inc. (EDIT) stock reflect a positive outlook for the company. Investors will likely benefit from closely following the company’s progress and keeping up with analyst ratings in order to make an informed decision on whether or not to buy EDIT stock.
Market Price
Analysts have been closely examining Editas Medicine Inc. (EDIT) stock in recent weeks as the biotech company continues to make waves in the industry. On Wednesday, EDITAS MEDICINE stock opened at $7.3 and closed at $7.4, up by 4.2% from its previous closing price of 7.1. This follows an overall positive month of trading for EDIT stock, with the company’s share price increasing steadily since the beginning of April. Analysts believe that this increase can be attributed to the company’s recent successful clinical trials as well as its partnerships with top biomedical companies.
Furthermore, many investors are optimistic about the potential for EDIT stock to grow significantly in the coming months and years. With analysts’ ratings leaning towards being favorable, it looks like EDIT stock will continue to have a bullish outlook in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Editas Medicine. More…
| Total Revenues | Net Income | Net Margin |
| 19.71 | -220.43 | -1118.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Editas Medicine. More…
| Operations | Investing | Financing |
| -177.35 | 114.07 | 1.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Editas Medicine. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 514.32 | 153.64 | 5.24 |
Key Ratios Snapshot
Some of the financial key ratios for Editas Medicine are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.3% | – | -1146.3% |
| FCF Margin | ROE | ROA |
| -920.6% | -36.4% | -27.5% |
Analysis
At GoodWhale, we analyzed the fundamentals of EDITAS MEDICINE and came to the conclusion that it has an intermediate health score of 4/10 when considering its cashflows and debt. This means that EDITAS MEDICINE may be able to sustain future operations in times of crisis. We conclude that this type of company may be of interest to certain types of investors, as it is strong in terms of asset but weaker in terms of growth, dividend and profitability. More…
Peers
In the world of gene-editing, three companies have emerged as leaders in the race to develop CRISPR-based treatments: Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG. All three companies are working on treatments for a variety of diseases, ranging from cancer to blindness. However, only Editas has begun to clinical trials on humans. This gives them a significant advantage over their competitors. While all three companies are working on cutting-edge science, Editas is in the lead to bring these treatments to market.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics Inc is a genomic editing company. Its technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
As of 2022, Intellia Therapeutics Inc has a market cap of 4.19B and a Return on Equity of -43.06%. The company’s technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. Intellia Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. Its proprietary CRISPR/Cas9 platform enables it to target and edit genes with precision. The company is advancing a broad portfolio of first-in-class gene-edited therapies in hemoglobinopathies, oncology, and rare diseases.
– Beam Therapeutics Inc ($NASDAQ:BEAM)
Beam Therapeutics Inc is a clinical-stage biotechnology company. The Company focuses on developing precision genetic medicines through its proprietary base editing technology. Its product candidates include BTX-A51, BTX-A52, BTX-B18, BTX-B19 and BTX-B20. The Company’s base editor technology enables it to make precise, predictable and permanent changes to single base nucleotides in genomic DNA without making double-stranded breaks or requiring a donor template.
Summary
Editas Medicine Inc. (EDIT) is currently trading at an attractive price, according to analysts. The stock has been upgraded by several major brokerages and its price has been steadily moving up in recent weeks. The company has also benefited from clinical progress in its leading product candidates, which could drive further upside in the stock in the near term.
Additionally, Editas has multiple partnerships with industry-leading firms that could help it to expand its pipeline of innovative therapies. Overall, EDIT appears to be an attractive investment opportunity for those looking for exposure to the biotechnology sector.
